https://orcid.org/0000-0002-1964-5824
References
- Herring WJ, Connor KM, Snyder E, et al. Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials. J Clin Sleep Med. 2016;12(9):1215–1225.
- Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136–148.
- Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–471.
- Asai Y, Sano H, Miyazaki M, et al. Suvorexant (Belsomra((R)) tablets 10, 15, and 20 mg): Japanese drug-use results survey. Drugs RD. 2018;19(1):27–46.
- Herring WJ, Connor KM, Snyder E, et al. Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials. Am J Geriatr Psychiatry. 2017;25(7):791–802.
- Mishima K, editor. Clinical practice guideline for the proper use and cessation of hypnotics. 2013.
- Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69(8):440–447.
- Soyka M, Longo DL. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147–1157.
- Pillai V, Roth T, Roehrs T, et al. Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: an examination of response and remission rates. Sleep. 2017;40(2). DOI:10.1093/sleep/zsw044
- Hatano M, Kamei H, Inagaki R, et al. Assessment of switching to suvorexant versus the use of add-on suvorexant in combination with benzodiazepine receptor agonists in insomnia patients: a retrospective study. Clin Psychopharmacol Neurosci. 2018;16(2):184–189.